{
    "clinical_study": {
        "@rank": "40041", 
        "arm_group": [
            {
                "arm_group_label": "S-303 Treated Red Blood Cells", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive S-303 treated red blood cells (RBCs)."
            }, 
            {
                "arm_group_label": "Conventional, untreated Red Blood Cells", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive conventional, untreated red blood cells (RBCs)."
            }
        ], 
        "brief_summary": {
            "textblock": "The clinical study will assess the in-vitro characteristics of red blood cells (RBCs) per\n      the European Union (EU) criteria for leukocyte depleted RBCs in additive solution and\n      evaluate the safety and efficacy of S-303 treated RBCs in a patient population requiring RBC\n      transfusion support for acute anemia."
        }, 
        "brief_title": "Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Focus:Use of S303 RBCs in Patients With Acute Anemia", 
        "condition_browse": {
            "mesh_term": "Anemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u226518 years, of either gender.\n\n          2. Must be willing to use an acceptable form  of contraceptive while on study (as\n             approved by the Investigator or designee)\n\n          3. Must be readily available by telephone\n\n          4. Must provide an informed consent for study participation and have signed an ethics\n             committee (EC)-approved informed consent\n\n          5. Must have a negative cross match to S 303 red blood cells (RBCs) at study entry\n\n          6. Must have a blood type of either A+ or O+\n\n          7. Patients must have a likelihood of receiving a transfusion as determined by the\n             Investigator OR a Transfusion Risk Understanding Screening Tool (TRUST) Score of \u22653\n             at study entry\n\n          8. Must be scheduled to receive one of the following operative procedures:\n\n               -  Coronary artery bypass graft only, first procedure\n\n               -  Valve repair or replacement only, first procedure\n\n               -  A combination of first time Coronary Artery Bypass Graft (CABG) and valve repair\n                  or replacement\n\n        After consultation with the Medical Monitor, provision can be made to enroll patients who\n        may meet these general criteria but whose surgical procedure is not precisely described in\n        the above categories. Such patients will be classified as \"other\" with their explicit\n        condition reported with other study data.\n\n        Exclusion Criteria:\n\n          1. A positive pregnancy test result\n\n          2. Inability of patient to comply with the protocol in the opinion of the Investigator\n             or attending physician\n\n          3. Breast-feeding of an infant or child\n\n          4. Active autoimmune hemolytic anemia, or a positive Direct Antiglobulin Test (DAT)\n             result\n\n          5. Treatment with any medication that is known to adversely affect red blood cell\n             viability\n\n          6. Emergent or salvage surgical status at the time of surgery defined as follows:\n\n               -  Presence of ongoing ischemia including angina at rest despite maximal medical\n                  therapy\n\n               -  Acute evolving myocardial infarction within 24 hours before surgery\n\n               -  Pulmonary edema requiring intubation\n\n               -  Presence of shock or hemodynamic instability with or without circulatory support\n\n               -  Systolic blood pressure < 80 mm Hg and/or Cardiac Index < 1.8 despite medical\n                  intervention (intravenous inotropes or similar pharmacologic agents)\n\n               -  Cardiopulmonary resuscitation in the 24 hours prior to surgery or anesthesia\n                  induction\n\n               -  Requiring an intra-aortic balloon pump or ventricular assist device\n\n          7. Participation in any one of the following types of clinical studies either\n             concurrently or within the previous 28 days: investigational blood products,\n             pharmacologic agents or imaging materials, including dyes, investigational surgical\n             techniques, or devices. Studies of nutrition, psychology, or socioeconomic issues are\n             not grounds for exclusion\n\n          8. Current diagnosis of either chronic or acute renal failure (requiring dialysis) or a\n             serum creatinine greater than or equal to 1.8 mg/dL within 30 days prior to the start\n             of surgery\n\n          9. Current diagnosis of either chronic or acute hepatic insufficiency or a total serum\n             bilirubin greater than or equal to 2.0 mg/dL within 30 days prior to the start of\n             surgery\n\n         10. Pre-existing RBC antibody that may make the provision of compatible study red blood\n             cell (RBC) components difficult\n\n         11. Patients requiring plasma removal or irradiation of the RBC\n\n         12. Patients with prior history of severe allergic transfusion reactions\n\n         13. A positive cross match to S 303 treated RBC\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716923", 
            "org_study_id": "CLI 00070"
        }, 
        "intervention": [
            {
                "arm_group_label": "S-303 Treated Red Blood Cells", 
                "intervention_name": "S-303 Red Blood Cells (RBCs) - Test", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Conventional, untreated Red Blood Cells", 
                "intervention_name": "Conventional, untreated red blood cells (RBCs) - Control", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 23, 2013", 
        "location": {
            "contact": {
                "email": "arndt.kiessling@kgu.de", 
                "last_name": "Arndt H Kiessling, MD", 
                "phone": "49 69 6301 87015"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt", 
                    "country": "Germany"
                }, 
                "name": "Klinikum der J.-W.-G.-Universit\u00e4t Frankfurt"
            }, 
            "investigator": {
                "last_name": "Arndt H Kiessling, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S 303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia", 
        "other_outcome": [
            {
                "description": "Incidence of renal insufficiency, indicated by serum creatinine level >2 mg/dL WITH at least a 50% increase from pre-operative baseline OR a new requirement for therapy to treat renal insufficiency (dialysis)", 
                "measure": "Exploratory Endpoint - incidence of renal insufficiency", 
                "safety_issue": "No", 
                "time_frame": "Daily on days 0 through 6"
            }, 
            {
                "description": "Incidence of hepatic insufficiency, indicated by total bilirubin that is >2 times the upper limit of normal AND represents at least a 50% increase from the preoperative baseline", 
                "measure": "Exploratory Endpoint - incidence of hepatic insufficiency", 
                "safety_issue": "No", 
                "time_frame": "Daily on days 0 through 6"
            }, 
            {
                "description": "Cardiopulmonary function at the time of first ambulation and at the time of discharge, as measured by a standardized 6 Minute Walk Test (6MWT)", 
                "measure": "Exploratory endpoint - Cardiopulmonary function", 
                "safety_issue": "No", 
                "time_frame": "Day 7 and 13"
            }
        ], 
        "overall_contact": {
            "email": "arndt.kiessling@kgu.de", 
            "last_name": "Arndt H Kiessling, MD", 
            "phone": "49 69 6301 87015"
        }, 
        "overall_official": {
            "affiliation": "Klinikum der J.-W.-G.-Universit\u00e4t Frankfurt", 
            "last_name": "Arndt H Kiessling, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The mean hemoglobin content per red blood cell (RBC) component compared between the treatment groups", 
                "measure": "Primary Efficacy Endpoint - mean hemoglobin content", 
                "safety_issue": "No", 
                "time_frame": "Day 2"
            }, 
            {
                "description": "The frequency of adverse events (related and unrelated to study RBC components) will be compared between the treatment groups.", 
                "measure": "Primary Safety Endpoint - Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }
        ], 
        "removed_countries": {
            "country": "France"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of RBC components that have adenosine-5'-triphosphate (ATP) levels of greater than 2 \u03bcmol/L", 
                "measure": "Secondary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Day 35"
            }, 
            {
                "description": "Proportion of RBC components that meet the European Union (EU) guideline for hemoglobin content, hematocrit, and hemolysis at the end of storage", 
                "measure": "Secondary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Day 35"
            }, 
            {
                "description": "Proportion of RBC components that have plasma-free hemoglobin levels corresponding to \u2264 0.8% hemolysis", 
                "measure": "Secondary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Day 35"
            }
        ], 
        "source": "Cerus Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cerus Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}